Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics

317 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
317
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
9
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics

  1. 1. Epigenomics, Present and Future Applications forPharmaceuticals and DiagnosticsReport Details:Published:August 2012No. of Pages: 160Price: Single User License – US$3995"Mabs" and molecular tests are among the growth industries of pharmaceuticals and diagnostics,but they may have competition long-term from an unexpected source. Epigenomics is a potentialgame-changer in the clinical therapeutics market and significant in testing as well. It refers totechnologies involving changes in genetic material that find their origins in causes other than basepairs alterations in the DNA of the host. Examples of such changes include DNA methylation andhistone acetylation, both of which have been known for many years to cause changes in geneexpression. This report Epigenomics, Present and Future Applications for Pharmaceuticals andDiagnostics describes the progress that has been made in our understanding of the basic scienceof epigenomics and considers the practical accomplishments being reported by the private sector.Epigenomics constitutes a challenge to the long held paradigm of DNA base pair sequences asthe prime determinant of the phenotype. Because of this profound intellectual shift, a vast newarea of biological investigation is rapidly unfolding. This presents significant opportunities forunderstanding disease processes and developing the means of combating them.Epigenomic Mechanisms Discussed in the report include:•DNA methylation•Histone Acetylation•Histone Phosphorylation•Methylation•Sumoylation•Histone “chaperones”•MicroRNAs (miRNAs)The examination of many diseases in a completely new light means there exist a wealth ofopportunities to develop new diagnostic and therapeutic approaches. At the same time it meansthat outdated concepts will have to be revised. This report looks at the science behindepigenomics and deals with opportunities for product development based on epigenetictechnologies and the outlook for the future in this exciting area of pharmaceutical technologies. Indoing so, the report provides:
  2. 2. •Discussion of the Basic Science and Mechanisms Behind Epigenomics•Activities of Top Companies in the Market•Interviews with Researchers and Private Sector Leaders•Market Estimates for Current Epigenomic Drugs and Forecast to 2017•Market Estimates for Current Epigenomic Diagnostics and Comparison to Next Gen Cancer Diagnostics Market•Analyst Conclusions Regarding the Future Market for Epigenomics•Key Healthcare Segments Impacted by Epigenomics•Examples of Clinically Relevant Epigenetic Biomarkers•Currently Approved Epigenomic Drugs•Epigenetic Drivers of Disease•Pharmaceutical R&D: A Need for Better Returns•Look at Applications in Alzheimer’s Disease, Mental Illness, Auto-Immune Diseases, Autism and Cardiovascular DiseaseThe report strives to predict the potential for epigenomics while reminding market-watchers of thechallenges and possible limiting factors in this market. As the report states:"In the examination of Google hits for “Epigenomics,” the phrases “exciting”, “state of the art”,“cutting edge”, “innovative”, “breakthrough” and other clichés are encountered over and over.These terms are frequently employed to cover up ideas, concepts and scientific discoveries thatmay NOT be cutting edge or state of the art and may be past their time, or may never havereached their time. For this reason the report will consider which of these technologies have valueand may be ripe for exploitation."The study of epigenomics today finds itself at a tuningpoint, with many unanswered questions anda proliferation of opportunities forproducts based on the constant flow of new research findings. This report is essential for pharmaceutical and diagnostic marketers looking to develop futurebusiness plans and determine opportunities in a promising field.Get your copy of this report @http://www.reportsnreports.com/reports/190910-epigenomics-present-and-future-applications-for-pharmaceuticals-and-diagnostics.htmlMajor points covered in Table of Contents of this report includeTable of ContentsCHAPTER ONE: EXECUTIVE SUMMARYThe Basic Science of Epigenetics- Basic Life Science R&DEpigenetics and DiagnosticsOutlook for epigenetics R&DCHAPTER TWO: THE BASIC SCIENCE OF EPIGENETICSA New Look at Health and Disease.
  3. 3. LamarckWeissmannThe History of Epigenetics to the PresentWhat This Report CoversWhat is Epigenetics?The concept.A New Level of ChallengeImplications for the Healthcare industryThe Big Picture: An interview with Dr. Michael SkinnerThe Molecular Biology of Epigenetic Control MechanismsDNA methylationHistone acetylation and other modificationsComplex; not well understoodHistone AcetylationHistone phosphorylationMethylationSumoylationHistone “chaperones”MicroRNAs (miRNAs)Summary, ConclusionsCHAPTER THREE: EPIGENETIC AND DIAGNOSISEpigenetic drivers of diseaseEpigenetics and DNA methylationRole of histonesEarly cancer diagnosisMethylation MarkersChallenges in the Identification of Epigenetic Involvement in Non-Cancerous DiseasesSummary, ConclusionsCHAPTER FOUR: MARKET DRIVERSEpigenetics and Therapeutics: Market by major diseasesCancersHypo/HypermethylationAnti-Cancer TherapyCovalent histone modificationsAberrant miRNA expressionAutoimmune dysfunctionCardiovascularMental Disorders
  4. 4. A classic Vision of Mental IllnessSchizophreniaBipolar disorderAutismAlzheimers DiseaseSpinal muscular Atrophy (SMA)Parkinsons DiseaseImprinting DisordersPraeder-Willi SyndromeAngelman SyndromeBeckwith-Wiedemann SyndromeFragile X SyndromeFriedreichs AtaxiaConcluding on a Cautionary NoteCHAPTER FIVE: COMPANIES ACTIVE IN EPIGENOMICSDiagnostic companiesEnzo Life SciencesEpigenomics AGEpiontisExact SciencesIlluminaNovus BiologicalsOncomethylome SciencesValirxVolition SingaporeTherapeutic CompaniesAcetylon PharmaceuticalsAcylin TherapeuticsCellCentricCeldexCelgeneCelzome (UK/DE)Chroma TherapeuticsConstellation PharmaEisai Co. LtdEpitherapeuticsEpiZymeMethyl GeneNovartis:Orion
  5. 5. RaNA TherapeuticsSyndax Pharmaceuticals Inc.ValiRX (UK)Epigenetics research products supply companiesActive MotifDiagenodeEpigentekLife TechnologiesQiagenSigma-AldrichZymo Research ProductsSummary, ConclusionsCHAPTER SIX: OUTLOOK FOR THE EPIGENETICS MARKETGrowth in World Markets; OverallDim Prospects for Pharma: How to Upend themUpsides, Opportunities: A huge market for epigenetic-based cancer treatments.The IVD marketThe Overall IVD MarketSpecific Epigenetic IVD market breakdownPersonalized medicine and epigeneticsIndustry Challenges and Strategic RecommendationsCompetitive landscapeTotal Epigenetics Market 2008-2017Market Drivers and RestraintsMarket Forecasts and Competitive AnalysisRevenue ForecastsCompetitive StructureCompetitive MetricsMarket Share Analysis: Product segmentsWW Epigenetic Market 2008-2017North AmericaEUJapanAsia PacificOminous signs from ChinaThe Way ForwardSouth AmericaSummary, ConclusionsTable Of Exhibits
  6. 6. CHAPTER ONE: EXECUTIVE SUMMARYTable 1-1:The most common epigenetic alterationsCHAPTER TWO: THE BASIC SCIENCE OF EPIGENETICSFigure 2-1 Timeline of epigenetic discoveries ourtesy Constellation PharmaTable 2-1 The most common epigenetic alterationsFigure 2-2 Agouti MiceFigure 2-3 Classic DNA methylation reactionFigure 2-4 The molecule 5-hydroxymethylcytosineFigure 2-5 DNA molecule wrapped twice around a Hisotne Octamer to make a NucleosomeTable 2-2 Varieties of histone modification and their propertiesFigure 2-6 Acetylation and deacetylation of lysene residuesFigure 2-7 Shilatifard A. 2008CHAPTER THREE: EPIGENETIC AND DIAGNOSISTable 3-1: Examples of Clinically Relevant Epigenetic BiomarkersCHAPTER FOUR: MARKET DRIVERSTable 4-1: Currently FDA-approved Epigenetic-Based DrugsFigure 4-1: Structures of (A) 5-aza 2-deoxycytidine (5 aza - dC, decitabine) and (B) zebularineFigure 4-2: U.S. FDA-approved Epigenetic-Acting DrugsTable 4-3: Prevalance of Autism as a Function Time, 200-2008Table 4-4: Current Autism TherapiesFigure 4-3: Map of the 11p15 imprinted regionCHAPTER FIVE: COMPANIES ACTIVE IN EPIGENOMICSTable 5-1: Some Important Epigenetics Diagnostics CompaniesTable 5-2: The Epigenetics Land Grab: R&D from Major Pharma CompaniesFigure 5-2: JUN/EPIZYME An Example of one of Epizymes inhibitors interacting with anepigenetic enzymeFigure 5-3: Structure of LBH589 (panobinostat)Figure 5-4: Action of PanbinostatFigure 5-5: Structure of EntinostatCHAPTER SIX: OUTLOOK FOR THE EPIGENOMICS MARKETTable 6.1:GNP Growth by Country, RegionTable 6.2: Conflicting Worldwide Economic Drivers And Their Impact On EpigenomicsTechnologiesFigure 6.1: Vast Expenditures, Poor ReturnsTable 6.3: Guidelines For A New Stage Of Drug DevelopmentTable 6.4: Epigenomics Therapeutics Market, 2011 and 2017 (millions)Table 6.5: Global Pharma Market, 2010 and 2015 (billions)Figure 6.2: Epigenomic Drug Market, 2011 and 2017Table 6.6: FDA-Approved Epigenetic Anti-Cancer AgentsFigure 6.3: Epigenomics Diagnostics Market, 2010 and 2015Table 6.7: Next Gen Cancer Diagnostics Market, 2010-2015
  7. 7. Table 6.8: Epigenomics in Cancer Diagnostics, 2010-2015Table 6.9: Total IVD Market 2007-2011Table 6.10: Some Current Epigenomics Research GoalsTable 6.11: Cancer Diagnostics MarketTable 6.12: Some Major Companies And Their ActivitiesFigure 6.4: Publications on Epigenomics and Cardiovascular DiseaseTable 6.13: Takeda regional Portfolio Blance As a BellweatherContact: sales@reportsandreports.com for more information.

×